US Oncologist Survey: Optimizing Treatment for Advanced Prostate Cancer


March 11, 2011
52 Pages - SKU: TAG6232439
License type:
Table of Contents Search inside this report Related Reports
Countries covered: United States
Patient case scenarios that progressively unfold, presented to 154 oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment choices, factors that influence their decisions, barriers to optimal treatment and confidence in treatment and management of patients. This primary research provides the oncology prescribing information that you are missing, directly from high-prescribing US Oncologists on the treatment of patients with advanced prostate cancer.

Case highlights include:
  • Rising PSA in a patient without documented metastatic disease
  • Asymptomatic castration resistant metastatic disease
  • Symptomatic metastatic disease
  • Symptomatic disease in an elderly patient
Treatment decisions for advanced stages of cancer are difficult to track as information quickly changes along with the introduction of new information and products impacting oncologists’ decisions. This series of reports will allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.

This report allows you to:
  • Understand what occurs with actual patients
  • Access the most up-to-date prescribing trends
  • Gain actionable data for developing and improving your market strategies
  • Pinpoint needs of your target audience
  • Focus resources to maximize the effectiveness of your budget
  • Understand where your product fits
  • Understand where your competitor’s product fits
  • Design messages to advance brand performance
Patient case scenarios that progressively unfold, presented to 154 oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment choices, factors that influence their decisions, barriers to optimal treatment and confidence in treatment and management of patients. This primary research provides the oncology prescribing information that you are missing, directly from high-prescribing US Oncologists on the treatment of patients with advanced prostate cancer.


Additional Information

Report Excerpt

Introduction

Metastatic prostate cancer is a cancer that has spread outside the prostate gland to the bladder or rectum as well as lymph nodes, bones or other areas. While treatment can control its spread and related symptoms, currently no treatment provides a cure. Treatment selection depends on many factors including previous treatment, site of recurrence, comorbid conditions, and patient preferences. Some men with a rising prostate-specific antigen (PSA) are treated similarly to those with advanced prostate cancer.

In prostate cancer, testosterone can cause prostate tumors to grow. Drugs, surgery, and other hormones are used to reduce testosterone or to block it. Androgen deprivation therapy (ADT) is usually recommended first. If cancer returns following ADT, the cancer is termed androgen resistant. In addition to ADT, secondary hormone therapy may be considered. When patients stop responding to all forms of hormone treatment, the cancer is termed castrate resistant prostate cancer. The next step in treatment is chemotherapy or immunotherapy. If cancer spreads to the bones, ADT may control the cancer that has spread to the bones. Radiation may also relieve the pain.
Chapter 1: Introduction
Table 1. Treatment Options in Advanced Prostate Cancer
Chapter 2: Respondent Demographics
Table 2.1 Eligibility Criteria for Survey Participation
Figure 2.1 Gender of Survey Respondents
Figure 2.2 Years Since Medical School Graduation
Figure 2.3 Practice Settings
Figure 2.4 Practices in NCI Cancer Centers
Figure 2.5 Geographic Settings
Figure 2.6 Survey Respondents by States
Figure 2.7 Number of Physicians in Practice Groups
Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen
Chapter 3: Treatment of a patient with increased PSA and adenocarcinoma
Next step in a patient with increased PSA and adenocarcinoma
Figure 3.1
Tests to be performed at this time with the patient
Figure 3.2
Confidence in treating to optimal outcome
Figure 3.3
Treatment decision with disease progression
Figure 3.4
Treatment decision with disease progression
Figure 3.5
Factors that influenced treatment
Figure 3.6
Chapter 4: Elderly patient treated for Gleason’s 7 adenocarcinoma, increased PSA 18 months later 23
Barriers to optimal treatment
Figure 4.1
Confidence in treating to optimal outcome
Figure 4.2
Treatment following rising PSA on leuprolide
Figure 4.3
Treatment decision upon disease progression
Figure 4.4
Factors that influenced treatment
Figure 4.5
Factors that influenced treatment by chosen agent
Table 4.1
Other agents that would be appropriate to include in therapy
Figure 4.6
Treatment upon rising PSA
Figure 4.6
Treatment upon further disease progression
Figure 4.7
Chapter 5: Patient with Gleason’s 3+4 adenocarcinoma and multiple metastases to pelvis and spine develops castration-resistant disease.
Appropriate Treatment
Figure 5.1
Confidence in treating to optimal outcome
Figure 5.2
Continuation of LHRH agonist
Figure 5.3
Factors Associated with Continuing LHRH Agonist
Figure 5.4
Cycles of docetaxel that the patient should receive
Figure 5.5
Next therapy with good performance status upon progressing after docetaxel
Figure 5.6
Chapter 6: Elderly patient with Gleason’s 5+5 and multiple metastases
Treatment of patient
Figure 6.1
Confidence in treating to optimal outcome
Figure 6.2
Treatment of patient’s progressive disease
Figure 6.3
Chapter 7: Summary
Appendix A: Survey Instrument

More Oncology/Hematology reports by The Assessment Group

US Market Changes in the Treatment of Advanced Melanoma by The Assessment Group
Progressively unfolding patient case scenarios were presented to 200 U.S. oncologists, who manage patients with advanced melanoma, to understand differences in clinical decisions and the ...
US Market Changes in the Treatment of Non-Hodgkin's Lymphoma by The Assessment Group
The purpose of this research study is to examine the current and evolving practice patterns of oncologists in managing advanced non-Hodgkin’s lymphoma. A survey ...
US Market Changes in the Treatment of Advanced Prostate Cancer by The Assessment Group
Progressively unfolding patient case scenarios were presented to 151 U.S. oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. ...
US Market Changes in the Treatment of Advanced Lung Cancer by The Assessment Group
The purpose of this study is to examine changes in the market for therapeutics used in the treatment of advanced lung cancer by examining longitudinal ...
See all reports like this >>

More United States Oncology/Hematology reports

US Cancer Diagnostics Market: Innovative Technologies and Emerging Business Opportunities by Venture Planning Group
This report contains 620 pages, 103 tables and presents a comprehensive analysis of the US cancer diagnostics market, including: Major issues pertaining to the US laboratory ...
US Proton Therapy Market Analysis to 2017 by RNCOS
According to most Oncologists, about 60% of all cancer patients undergo some sort of radiation therapy during their course of treatment. Despite advances in technology ...
United States Oncology Drug Delivery Preferences and Opportunities in Cancer Drug Delivery by Frost & Sullivan
Drug delivery is an important area of drug development in the pharmaceutical and biotechnology industry. In Oncology, developers are interested in understanding the opportunities and ...
The US Hematology Market: Instrument and Consumable Sales Forecasts by Market Segment, Key Supplier Shares by Venture Planning Group
This report provides an overview of the US hematology market, including sales and market shares of leading instrument and consumable suppliers, as well as test ...
See all reports like this >>

More United States reports

D&B Country RiskLine Report: The United States of America by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
D&B Country Report: The United States of America by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
Country Report United States January 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...
Coal - US - a snapshot (2010) by Mintel - Snapshots
Coal in US by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2010. This market covers consumption ...
See all reports like this >>

 

Research assistance

We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 

Related Markets


Oncology/Hematology Reports

 
 

Share this report


Other tasks

 
 

Join Alert Me now!

Receive bi-weekly email alerts on new market research

Sign up today!